rte.ieOct 13$JNJ

J&J beats earnings estimates; Middle East war hits sales

Johnson & Johnson reported Q3 revenue of $25.4B, beating estimates, with strong pharmaceutical sales led by Tremfya. Medical device sales grew modestly, impacted by geopolitical issues. Adjusted earnings were $2.59 per share, topping expectations. The company raised its full-year sales and earnings forecasts.

Original reporting

rte.ie

Published Oct 13, 2026, 10:52 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 13, 2026, 2:32 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

J&J beats earnings estimates; Middle East war hits sales — source image — Source · rte.ie

Decision brief

The 30-second read

$JNJBullishHigh

Why it matters

The earnings beat and guidance raise are likely to support a short-term rally in JNJ, though geopolitical pressures on device sales may temper enthusiasm.

Market read

Strong earnings and guidance lift for a mega-cap health company provide a clear trading catalyst.

What to watch

Potential headwinds from geopolitical tensions could affect future device revenue growth.

Relevance 9/10Novelty 9/10Timing: post-market today

Background

The article summarizes Johnson & Johnson's Q3 earnings release, highlighting revenue, EPS, segment performance, and updated guidance.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$JNJBullishHigh confidence

Context

Johnson & Johnson reported Q3 earnings beating estimates and raised full-year sales and earnings guidance.

Expected impact

likely upward pressure as investors price in the beat and higher guidance

Evidence & confidence

The company posted revenue above consensus and lifted its FY sales and EPS midpoint, which typically drives buying interest.

Market effects

Sector

Healthcare sector may see modest lift as a large-cap pharma beats expectations.

Regional

U.S. markets could see a small boost from the earnings surprise.

Global

Limited; primarily impacts U.S. and global healthcare investors.

Counterpoint

What could challenge this read

Some investors may worry about the drag from Middle East conflict on medical devices sales.

Key entities

company
Johnson & Johnson
U.S.-listed healthcare conglomerate reporting Q3 results.
executive
Joe Wolk
Chief Financial Officer of Johnson & Johnson providing commentary.

Read at source ← All news

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

finance.yahoo.comNov 4

$JNJMedAI 8/10

Johnson & Johnson’s Javelin Catheter Met Both Trial Goals and Its Impella Data Pushed Back on a Negative Study. Here’s What It Doesn’t Settle

Johnson & Johnson (JNJ) reported positive results for its Javelin catheter, meeting both primary goals in a pivotal study. Impella heart pump data showed lower death rates than a previous negative study. Javelin is still under FDA review, and Impella's recovery depends on future trials. JNJ's cardiovascular unit saw a sales decline, with Impella contributing 1.6% of total revenue. Analysts project a ~25% total return for JNJ stock.

finance.yahoo.comNov 2

$JNJMed

TREMFYA® (guselkumab) reimbursed for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis for use in Ireland

Johnson & Johnson's TREMFYA (guselkumab) has been approved for reimbursement in Ireland for treating moderately to severely active Crohn’s disease and ulcerative colitis. The approval is based on Phase 3 trials showing significant clinical remission rates. According to the company, it offers a novel dual mechanism of action and improved outcomes for patients.

imt.ieNov 2

$JNJMed

J&J data show lower mortality with Impella in HRPCI than CHIP-BCIS3

Johnson & Johnson (J&J) presented data at a symposium showing lower mortality rates in high-risk PCI patients using Impella heart pumps compared to the CHIP-BCIS3 trial. Three analyses, involving 1,379 patients, reported 30-day mortality rates of 6.1% and 4.7%, and 90-day rates of 6.5%. J&J's heart recovery chief medical officer highlighted the importance of device usage and patient selection. The company continues studying Impella, with PROTECT IV trial results expected in 2027.

medicaldevice-network.comNov 2

$JNJMedAI 8/10

J&J's Javelin Meets Pivotal Coronary Study Goals; Highlights Impella Survival Data At TCT

Johnson & Johnson (JNJ) reported that its Shockwave Javelin coronary catheter met primary endpoints in the FORWARD CAD study, with 93.6% successful lesion crossing and 93.4% safety. The study involved 158 patients. Separately, J&J shared favorable Impella data from three analyses, showing low mortality rates. JNJ closed at $273.20, down 0.73%.

rttnews.comNov 2

$JNJHigh

PROTEUS: Perioperative Apalutamide Plus ADT Improves EFS in High-Risk Locally Advanced Prostate Cancer

A substudy of the phase 3 PROTEUS trial, presented at ESMO Congress 2026, showed that perioperative apalutamide plus ADT reduced recurrence or death risk by 62% in high-risk prostate cancer patients. The study, supported by Johnson & Johnson, met primary endpoints, including event-free survival and metastasis-free survival. Lead author Alberto Briganti suggested the treatment could become a standard option for eligible patients.

endocrinologyadvisor.comNov 2